Vanderbilt University

University of Texas System

The Johns Hopkins University

University of Pennsylvania

The University of North Carolina at Chapel Hill

Baylor College of Medicine

Icahn School of Medicine at Mount Sinai

Modernatx, Inc.

James E Crowe, Jr

Andrew I Flyak

Alexander Bukreyev

Scott A Smith

Philipp Ilinykh

George M Shaw

Stuart Campbell Ray

Justin R Bailey

Pavlo Gilchuk

Drew Weissman

Ralph Baric

William Messer

Terence Dermody

Robert Carnahan

A Ruklanthi De Alwis

Wahala M P B Wahala

Seth Zost

Laurie Silva

Giuseppe Ciaramella

Sunny Himansu

Mary K Estes

Eva M Harth

Eric P Skaar

Bryan Voss

Aravinda De Silva

Heidi E Hamm

Sharon K Hamilton

Iuliia Gilchuk

Gopal Sapparapu

Matthew R Vogt

Isaac Thomsen

Aravinda M De Silva

Buddy Creech

Kui Huang

Christopher F Basler

Jarrod Mousa

The present disclosure is directed to human and engineered antibodies and fragments thereof binding to enterovirus D68 (EV-D68), engineered cells producing the same, and of using the antibodies and fragments thereof in methods for both diagnosing and treating EV-D68 infections. Also disclosed are vaccine formulations comprising one of more of the antibody and fragments thereof, as well as vectors encoding the same.

Human monoclonal antibodies to enterovirus D68

The present disclosure is directed to antibodies binding previously undefined epitopes on influenza A virus hemagglutinin and methods for use thereof.

Human monoclonal antibodies to a new universal influenza A hemagglutinin head domain epitope

The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.

Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus

The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof.

Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

The present disclosure is directed to antibodies binding to and neutralizing norovirus and methods for use thereof. Thus, in accordance with the present disclosure, there is provided a method of detecting a norovirus infection in a subject comprising (a) contacting a sample from the subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences; and (b) detecting norovirus in the sample by binding of the antibody or antibody fragment to a norovirus antigen in the sample.

Human monoclonal antibodies that neutralize pandemic GII.4 noroviruses

The present disclosure is directed to antibodies binding to and neutralizing Yellow Fever Virus and methods for use thereof.

Human monoclonal antibodies against yellow fever virus and uses therefor

The present disclosure is directed to antibodies binding to and neutralizing West Nile virus and methods for use thereof.

Human West Nile virus antibodies and methods of use therefor

The present disclosure is directed to antibodies binding to and inhibitingand methods for use thereof.

Human monoclonal antibodies toIsd proteins and uses thereof

The present disclosure is directed to antibodies binding to and neutralizing Japanese Encephalitis virus and methods for use thereof.

Human Japanese Encephalitis Virus antibodies and methods of use therefor

The present disclosure is directed to human antibodies binding to and neutralizing ebolavirus and methods for use thereof. A further embodiment involves a monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences. In yet another embodiment, there is provided a hybridoma or engineered cell encoding an antibody or antibody fragment. An additional embodiment comprises a vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences. In still a further embodiment, there is provided a method of protecting the health of a placenta and/or fetus of a pregnant a subject infected with or at risk of infection with ebolavirus comprising delivering to said subject the antibody or antibody fragment.

Pan-ebola virus neutralizing human antibodies and methods of use therefor

The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof.

Antibody-mediated neutralization of chikungunya virus

This disclosure relates to compositions and methods for treating and preventing chikungunya virus infection by delivering polynucleotides encoding anti-chikungunya virus antibodies to a subject. Compositions and treatments provided herein include one or more polynucleotides having an open reading frame encoding an anti-chikungunya virus antibody heavy chain or fragment thereof and/or an anti-chikungunya virus antibody light chain or fragment thereof. Methods for preparing and using such treatments are also provided.

Polynucleotides encoding anti-chikungunya virus antibodies

The present disclosure is directed to antibodies binding to and neutralizing Zika virus and methods for use thereof.

Human zika virus antibodies and methods of use therefor

The present disclosure is directed to antibodies binding to and neutralizing Poxvirus and methods for use thereof.

Human orthopoxvirus antibodies and methods of use therefor

Growing community of inventors

Nashville, TN, United States of America

James E Crowe, Jr